Intimation to Stock Exchange
2019-2020
Schedule of Con Call Meeting
June 04, 2020Notice of Board Meeting for Approval of Audited Accounts
June 01, 2020Disclosure under Regulation 30 of LODR Regulations 2015
April 13, 2020Closure of Trading Window
March 30, 2020Appointment of Dr. (Ms.) Vasudha V. Kamat as an Additional Independent Director of the Company
March 25, 2020Indoco's Q3FY20 revenues grow at 14.3%
January 23, 2020Schedule of Con Call Meeting
January 15, 2020Intimation of Board Meeting - Unaudited Financial Results for the quarter ended December 31,2019
January 06, 2020Indoco receives Approval for Febuxostat Tablets from USFDA
December 31, 2019Indoco receives EU GMP from UK-MHRA for its Sterile facility in Goa (Plant II)
December 16, 2019Indoco's CRO – AnaCipher receives EIR from USFDA
November 26, 2019Indoco receives EIR for its manufacturing facilities in Goa (Plant II & III)
November 25, 2019Indoco's Q2FY20 revenues grow at 21%
October 30, 2019Indoco's Clinical Research Organisation receives zero 483s from USFDA
October 18, 2019Indoco successfully concludes USFDA inspection at Goa Plant II
October 16, 2019Schedule of Con Call Meeting
October 14, 2019Intimation of Board Meeting - Unaudited Financial Results for the Quarter and half year ended September 30, 2019
October 10, 2019Indoco receives ANDA approval for Rasagiline Tablets
October 07, 2019Indoco successfully completes UK-MHRA inspection at Goa Plant II
September 23, 2019UK-MHRA reinstates full GMP status for Indoco's Goa Plant I
September 13, 2019Credit Rating by ICRA
September 03, 2019Indoco's Q1FY20 revenues grow at 16%
August 13, 2019Indoco's CRO – ANACIPHER clears USFDA inspection with ZERO 483
August 12, 2019Schedule of Con Call Meeting
August 09, 2019Schedule of Con Call Meeting
July 16, 2019Indoco's Goa Plant I receives Warning Letter from USFDA
July 15, 2019Intimation of Board Meeting - Unaudited Financial Results for the First Quarter ended 30th June, 2019
July 01, 2019Closure of Trading Window
July 01, 2019Annual Secretarial Compliance Report for Financial year ended 31.03.2019
May 27, 2019USFDA retains the OAI status of Indoco's Goa Plant I
April 24, 2019Closure of Trading Window
April 04, 2019
2018-2019
Indoco's Q4FY19 Revenues at Rs. 245 Crores
May 29, 2019Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA
March 29, 2019Indoco Q3FY19 Revenues at Rs. 248 Crores
January 23, 2019Indoco Q2FY19 Revenues at Rs. 236 Crores
November 13, 2018Indoco declares Q1FY19 results
August 13, 2018
2017-2018
Indoco's operating margins grow by 18% at Rs. 38.5 Crores
May 30, 2018Indoco's Net Profit Q-o-Q grows at 29%
January 25, 2018Indoco’s Net Profit at Rs 19.76 Crores
November 07, 2017A Double Whammy – FDA Warning Letter & GST woes for Indoco
August 09, 2017
2016-17
Indoco's Revenue for FY17 up by 9%
May 26, 2017Indoco's Net Revenues Up by 6.2%
January 27, 2017Indoco's Net Revenues Up by 11% Q-o-Q
October 26, 2016Indoco's Net Revenues Up by 16% Q-o-Q Receives ANDA approval for Allopurinol tablets
July 29, 2016
2015-2016
Indoco Remedies Q4 net profit rises 6.7% to
20 crore aided by exports
May 26, 2017Indoco Remedies Q3 sales rises 19.6% as domestic business bounces back
January 29, 2016Indoco Remedies Q2 Net Revenues rise 9% Y-o-Y to
248 crores
October 30, 2015Indoco Remedies Q1FY16 PAT grows QoQ at 8% to Rs. 20.3 Crores
July 30, 2015
2014-2015
Net Revenues of Indoco Remedies rise by 14% at Rs.212 Crores
May 27, 2015Indoco Remedies Q3 Profit After Tax (PAT) grows by 53%
January 30, 2015Indoco Remedies Q2 Profit After Tax (PAT) grows by 40%
October 21, 2014Indoco Remedies Q1 Net Profit up 118%
July 30, 2014